A pilot, open study of sertraline in outpatients with treatment-resistant depression (TRD) or with a history of TRD who responded but later relapsed

George I. Papakostas, Timothy Petersen, John J. Worthington, Pamela A. Roffi, Jonathan E. Alpert, Maurizio Fava, Andrew A. Nierenberg

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

While most depressed patients are prescribed a selective serotonin reuptake inhibitor (SSRI) as an initial treatment, the use of SSRIs as a second or third-line treatment for depression is not as prevalent. This trial assessed the efficacy of sertraline for patients with treatment-resistant depression (TRD) or patients with a history of TRD who responded but later relapsed. Twelve patients with TRD who had not responded to a number of antidepressant trials (n = 7), or had responded but subsequently suffered a relapse (n = 5), were enrolled in an 8-week, open trial of sertraline. Both a completer analysis (n = 6) and an intent-to-treat (ITT) analysis (n = 12) were performed to evaluate sertraline response rates. Using a completer analysis, four patients (66.6%) were classified as responders; one (16.7%) as a partial responder and one (16.7%) as a non-responder. An ITT analysis resulted in five (41.7%) patients being classified as responders; one (8.3%) as a partial responder and six (50%) as non-responders. Of the four responders in the completer analysis, three (50%) achieved remission. Of the five responders in the ITT analysis, four (33.3%) achieved remission. Overall, two of seven (28.6%) non-responders and three of five (60.0%) relapsers responded to sertraline. The present results suggest the potential utility of sertraline for patients with TRD, or those with a history of TRD who responded but later relapsed, and warrant larger, placebo-controlled studies to further explore the potential role of sertraline for such patients.

Original languageEnglish (US)
Pages (from-to)293-296
Number of pages4
JournalInternational Clinical Psychopharmacology
Volume18
Issue number5
DOIs
StatePublished - Sep 2003
Externally publishedYes

Fingerprint

Treatment-Resistant Depressive Disorder
Sertraline
Outpatients
Serotonin Uptake Inhibitors
Antidepressive Agents
Placebos
Depression
Recurrence

Keywords

  • Antidepressant non-response
  • Depression
  • Medication switch
  • Refractory depression
  • Sertraline
  • SSRI
  • Treatment-resistant

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Psychiatry and Mental health
  • Neuroscience(all)
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

A pilot, open study of sertraline in outpatients with treatment-resistant depression (TRD) or with a history of TRD who responded but later relapsed. / Papakostas, George I.; Petersen, Timothy; Worthington, John J.; Roffi, Pamela A.; Alpert, Jonathan E.; Fava, Maurizio; Nierenberg, Andrew A.

In: International Clinical Psychopharmacology, Vol. 18, No. 5, 09.2003, p. 293-296.

Research output: Contribution to journalArticle

Papakostas, George I. ; Petersen, Timothy ; Worthington, John J. ; Roffi, Pamela A. ; Alpert, Jonathan E. ; Fava, Maurizio ; Nierenberg, Andrew A. / A pilot, open study of sertraline in outpatients with treatment-resistant depression (TRD) or with a history of TRD who responded but later relapsed. In: International Clinical Psychopharmacology. 2003 ; Vol. 18, No. 5. pp. 293-296.
@article{acbf5fd03a4744e1b2bb159cbcacd041,
title = "A pilot, open study of sertraline in outpatients with treatment-resistant depression (TRD) or with a history of TRD who responded but later relapsed",
abstract = "While most depressed patients are prescribed a selective serotonin reuptake inhibitor (SSRI) as an initial treatment, the use of SSRIs as a second or third-line treatment for depression is not as prevalent. This trial assessed the efficacy of sertraline for patients with treatment-resistant depression (TRD) or patients with a history of TRD who responded but later relapsed. Twelve patients with TRD who had not responded to a number of antidepressant trials (n = 7), or had responded but subsequently suffered a relapse (n = 5), were enrolled in an 8-week, open trial of sertraline. Both a completer analysis (n = 6) and an intent-to-treat (ITT) analysis (n = 12) were performed to evaluate sertraline response rates. Using a completer analysis, four patients (66.6{\%}) were classified as responders; one (16.7{\%}) as a partial responder and one (16.7{\%}) as a non-responder. An ITT analysis resulted in five (41.7{\%}) patients being classified as responders; one (8.3{\%}) as a partial responder and six (50{\%}) as non-responders. Of the four responders in the completer analysis, three (50{\%}) achieved remission. Of the five responders in the ITT analysis, four (33.3{\%}) achieved remission. Overall, two of seven (28.6{\%}) non-responders and three of five (60.0{\%}) relapsers responded to sertraline. The present results suggest the potential utility of sertraline for patients with TRD, or those with a history of TRD who responded but later relapsed, and warrant larger, placebo-controlled studies to further explore the potential role of sertraline for such patients.",
keywords = "Antidepressant non-response, Depression, Medication switch, Refractory depression, Sertraline, SSRI, Treatment-resistant",
author = "Papakostas, {George I.} and Timothy Petersen and Worthington, {John J.} and Roffi, {Pamela A.} and Alpert, {Jonathan E.} and Maurizio Fava and Nierenberg, {Andrew A.}",
year = "2003",
month = "9",
doi = "10.1097/00004850-200309000-00006",
language = "English (US)",
volume = "18",
pages = "293--296",
journal = "International Clinical Psychopharmacology",
issn = "0268-1315",
publisher = "Lippincott Williams and Wilkins",
number = "5",

}

TY - JOUR

T1 - A pilot, open study of sertraline in outpatients with treatment-resistant depression (TRD) or with a history of TRD who responded but later relapsed

AU - Papakostas, George I.

AU - Petersen, Timothy

AU - Worthington, John J.

AU - Roffi, Pamela A.

AU - Alpert, Jonathan E.

AU - Fava, Maurizio

AU - Nierenberg, Andrew A.

PY - 2003/9

Y1 - 2003/9

N2 - While most depressed patients are prescribed a selective serotonin reuptake inhibitor (SSRI) as an initial treatment, the use of SSRIs as a second or third-line treatment for depression is not as prevalent. This trial assessed the efficacy of sertraline for patients with treatment-resistant depression (TRD) or patients with a history of TRD who responded but later relapsed. Twelve patients with TRD who had not responded to a number of antidepressant trials (n = 7), or had responded but subsequently suffered a relapse (n = 5), were enrolled in an 8-week, open trial of sertraline. Both a completer analysis (n = 6) and an intent-to-treat (ITT) analysis (n = 12) were performed to evaluate sertraline response rates. Using a completer analysis, four patients (66.6%) were classified as responders; one (16.7%) as a partial responder and one (16.7%) as a non-responder. An ITT analysis resulted in five (41.7%) patients being classified as responders; one (8.3%) as a partial responder and six (50%) as non-responders. Of the four responders in the completer analysis, three (50%) achieved remission. Of the five responders in the ITT analysis, four (33.3%) achieved remission. Overall, two of seven (28.6%) non-responders and three of five (60.0%) relapsers responded to sertraline. The present results suggest the potential utility of sertraline for patients with TRD, or those with a history of TRD who responded but later relapsed, and warrant larger, placebo-controlled studies to further explore the potential role of sertraline for such patients.

AB - While most depressed patients are prescribed a selective serotonin reuptake inhibitor (SSRI) as an initial treatment, the use of SSRIs as a second or third-line treatment for depression is not as prevalent. This trial assessed the efficacy of sertraline for patients with treatment-resistant depression (TRD) or patients with a history of TRD who responded but later relapsed. Twelve patients with TRD who had not responded to a number of antidepressant trials (n = 7), or had responded but subsequently suffered a relapse (n = 5), were enrolled in an 8-week, open trial of sertraline. Both a completer analysis (n = 6) and an intent-to-treat (ITT) analysis (n = 12) were performed to evaluate sertraline response rates. Using a completer analysis, four patients (66.6%) were classified as responders; one (16.7%) as a partial responder and one (16.7%) as a non-responder. An ITT analysis resulted in five (41.7%) patients being classified as responders; one (8.3%) as a partial responder and six (50%) as non-responders. Of the four responders in the completer analysis, three (50%) achieved remission. Of the five responders in the ITT analysis, four (33.3%) achieved remission. Overall, two of seven (28.6%) non-responders and three of five (60.0%) relapsers responded to sertraline. The present results suggest the potential utility of sertraline for patients with TRD, or those with a history of TRD who responded but later relapsed, and warrant larger, placebo-controlled studies to further explore the potential role of sertraline for such patients.

KW - Antidepressant non-response

KW - Depression

KW - Medication switch

KW - Refractory depression

KW - Sertraline

KW - SSRI

KW - Treatment-resistant

UR - http://www.scopus.com/inward/record.url?scp=0041327979&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0041327979&partnerID=8YFLogxK

U2 - 10.1097/00004850-200309000-00006

DO - 10.1097/00004850-200309000-00006

M3 - Article

C2 - 12920390

AN - SCOPUS:0041327979

VL - 18

SP - 293

EP - 296

JO - International Clinical Psychopharmacology

JF - International Clinical Psychopharmacology

SN - 0268-1315

IS - 5

ER -